A 6-week, phase IIb, randomized, double-blind, placebo-controlled trial of Anyu Peibo capsules for the treatment of major depressive disorder in adults.

Ther Adv Psychopharmacol · 2023 · PMC10666694 · PMID 38022835

Europe PMC DOI

hedged sentence

0.0819

closest p · 1.6× alpha

0.0819

boldest claim

The sentences

did not reach statistical significancep = 0.0819so close (0.05 < p ≤ 0.1)

Although there were greater reductions in the MADRS score from baseline to week 6 in the Anyu Peibo capsule group compared to the placebo group, the difference did not reach statistical significance (least-squares mean difference, 2.07 points; 95% confidence interval, −0.27 to 4.41; p = 0.0819).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.